Consort Medical plc Given Buy Rating at N+1 Singer (CSRT)
Consort Medical plc (LON:CSRT)‘s stock had its “buy” rating reissued by equities researchers at N+1 Singer in a research report issued on Thursday. They currently have a GBX 1,100 ($18.25) target price on the stock, up from their previous target price of GBX 1,020 ($16.93). N+1 Singer’s price objective indicates a potential upside of 20.22% from the stock’s previous close.
Consort Medical plc (LON:CSRT) traded up 3.52% on Thursday, hitting GBX 947.178. The stock had a trading volume of 15,653 shares. Consort Medical plc has a 52-week low of GBX 839.9999 and a 52-week high of GBX 1113.00. The stock has a 50-day moving average of GBX 918.9 and a 200-day moving average of GBX 931.7. The company’s market cap is £273.3 million.
A number of other firms have also recently commented on CSRT. Analysts at FinnCap reiterated a “sell” rating on shares of Consort Medical plc in a research note on Thursday. Separately, analysts at Canaccord Genuity raised their price target on shares of Consort Medical plc from GBX 1,045 ($17.34) to GBX 1,182 ($19.62) in a research note on Thursday. They now have a “buy” rating on the stock. Finally, analysts at Shore Capital upgraded shares of Consort Medical plc to a “buy” rating in a research note on Wednesday, July 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of GBX 1,019.22 ($16.91).
Consort Medical plc is a healthcare company focused on medical technologies. The principal activities of the Company are the design, development and manufacture of specialty medical drug delivery devices and services to the pharmaceutical industry through its Bespak Division and disposable airway management products for critical care settings in hospitals and pre-hospital settings through its King Systems Division.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.